<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Head and Neck Tumors</journal-id><journal-title-group><journal-title xml:lang="en">Head and Neck Tumors</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли головы и шеи</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2222-1468</issn><issn publication-format="electronic">2411-4634</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">986</article-id><article-id pub-id-type="doi">10.17650/2222-1468-2024-14-2-98-107</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>TOPICAL</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>АКТУАЛЬНОЕ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Observation and treatment of patients with progressive metastatic differentiated thyroid cancer after establishment of radioiodine refractoriness</article-title><trans-title-group xml:lang="ru"><trans-title>Наблюдение и лечение больных прогрессирующим метастатическим дифференцированным раком щитовидной железы после установления радиойодрефрактерности</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3306-5906</contrib-id><name-alternatives><name xml:lang="en"><surname>Borodavina</surname><given-names>E. V.</given-names></name><name xml:lang="ru"><surname>Бородавина</surname><given-names>Е. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Ekaterina vladimirovna Borodavina</p><p>4 Koroleva St., Obninsk 249036</p></bio><bio xml:lang="ru"><p>Екатерина Владимировна Бородавина</p><p>249036 Обнинск, ул. Королева, 4</p></bio><email>smysmymrik2007@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2221-4088</contrib-id><name-alternatives><name xml:lang="en"><surname>Kutukova</surname><given-names>S.  I.</given-names></name><name xml:lang="ru"><surname>Кутукова</surname><given-names>С. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>1 Malaya Sadovaya St., Saint Petersburg 191023; 6–8, L’va Tolstogo St., Saint Petersburg 197022</p></bio><bio xml:lang="ru"><p>191023 Санкт-Петербург, ул. Малая Садовая, 1; 197022 Санкт-Петербург, ул. Льва Толстого, 6–8</p></bio><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4934-2012</contrib-id><name-alternatives><name xml:lang="en"><surname>Shurinov</surname><given-names>A. Yu.</given-names></name><name xml:lang="ru"><surname>Шуринов</surname><given-names>А. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>4 Koroleva St., Obninsk 249036</p></bio><bio xml:lang="ru"><p>249036 Обнинск, ул. Королева, 4</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1285-2182</contrib-id><name-alternatives><name xml:lang="en"><surname>Vasil’eva</surname><given-names>E. B.</given-names></name><name xml:lang="ru"><surname>Васильева</surname><given-names>Е. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>42 Blukhera St., Chelyabinsk 454087</p></bio><bio xml:lang="ru"><p>454087 Челябинск, ул. Блюхера, 42</p></bio><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8164-2261</contrib-id><name-alternatives><name xml:lang="en"><surname>Guz</surname><given-names>A. O.</given-names></name><name xml:lang="ru"><surname>Гузь</surname><given-names>А. О.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>42 Blukhera St., Chelyabinsk 454087</p></bio><bio xml:lang="ru"><p>454087 Челябинск, ул. Блюхера, 42</p></bio><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Grishkevich</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Гришкевич</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>29 Soboleva St., Ekaterinburg 620036</p></bio><bio xml:lang="ru"><p>620036 Екатеринбург, ул. Соболева, 29</p></bio><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Karateeva</surname><given-names>S. D.</given-names></name><name xml:lang="ru"><surname>Каратеева</surname><given-names>С. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>15 Baumana St., Perm 614066</p></bio><bio xml:lang="ru"><p>614066 Пермь, ул. Баумана, 15</p></bio><xref ref-type="aff" rid="aff6"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shakhmatova</surname><given-names>A. R.</given-names></name><name xml:lang="ru"><surname>Шахматова</surname><given-names>А. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>11/1 Delovaya St., Nizhny Novgorod 603093</p></bio><bio xml:lang="ru"><p>603093 Нижний Новгород, ул. Деловая, 11/1</p></bio><xref ref-type="aff" rid="aff7"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Slobodyanskiy</surname><given-names>R. S.</given-names></name><name xml:lang="ru"><surname>Слободянский</surname><given-names>Р. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>42 Blukhera St., Chelyabinsk 454087</p></bio><bio xml:lang="ru"><p>454087 Челябинск, ул. Блюхера, 42</p></bio><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Romanchuk</surname><given-names>O. V.</given-names></name><name xml:lang="ru"><surname>Романчук</surname><given-names>О. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>8 Sosensky Stan St., Kommunarka, Moscow 108814</p></bio><bio xml:lang="ru"><p>108814 Москва, п. Коммунарка, ул. Сосенский стан, 8</p></bio><xref ref-type="aff" rid="aff8"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0741-624X</contrib-id><name-alternatives><name xml:lang="en"><surname>Mukhitova</surname><given-names>M. R.</given-names></name><name xml:lang="ru"><surname>Мухитова</surname><given-names>М. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>29 Sibirskiy Trakt St., Kazan 420029</p></bio><bio xml:lang="ru"><p>420029 Казань, ул. Сибирский тракт, 29</p></bio><xref ref-type="aff" rid="aff9"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Karpovich</surname><given-names>M. P.</given-names></name><name xml:lang="ru"><surname>Карпович</surname><given-names>М. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>8 Sosensky Stan St., Kommunarka, Moscow 108814</p></bio><bio xml:lang="ru"><p>108814 Москва, п. Коммунарка, ул. Сосенский стан, 8</p></bio><xref ref-type="aff" rid="aff8"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dmitriev</surname><given-names>S. P.</given-names></name><name xml:lang="ru"><surname>Дмитриев</surname><given-names>С. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>11/1 Delovaya St., Nizhny Novgorod 603093</p></bio><bio xml:lang="ru"><p>603093 Нижний Новгород, ул. Деловая, 11/1</p></bio><xref ref-type="aff" rid="aff7"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Saypeeva</surname><given-names>O. S.</given-names></name><name xml:lang="ru"><surname>Сайпеева</surname><given-names>О. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>15 Baumana St., Perm 614066</p></bio><bio xml:lang="ru"><p>614066 Пермь, ул. Баумана, 15</p></bio><xref ref-type="aff" rid="aff6"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0864-6493</contrib-id><name-alternatives><name xml:lang="en"><surname>Tolpeykina</surname><given-names>K. A.</given-names></name><name xml:lang="ru"><surname>Толпейкина</surname><given-names>К. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>42 Blukhera St., Chelyabinsk 454087</p></bio><bio xml:lang="ru"><p>454087 Челябинск, ул. Блюхера, 42</p></bio><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tolstov</surname><given-names>S. S.</given-names></name><name xml:lang="ru"><surname>Толстов</surname><given-names>С. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>29B Moskovskaya St., Tambov 392000</p></bio><bio xml:lang="ru"><p>392000 Тамбов, Московская ул., 29В</p></bio><xref ref-type="aff" rid="aff10"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Makarova</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Макарова</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>5 Lyubimova St., Ivanovo 153040</p></bio><bio xml:lang="ru"><p>153040 Иваново, ул. Любимова, 5</p></bio><xref ref-type="aff" rid="aff11"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tyugina</surname><given-names>Ya. A.</given-names></name><name xml:lang="ru"><surname>Тюгина</surname><given-names>Я. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>5 Lyubimova St., Ivanovo 153040</p></bio><bio xml:lang="ru"><p>153040 Иваново, ул. Любимова, 5</p></bio><xref ref-type="aff" rid="aff11"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ovchinnikova</surname><given-names>E. G.</given-names></name><name xml:lang="ru"><surname>Овчинникова</surname><given-names>Е. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>11/1 Delovaya St., Nizhny Novgorod 603093</p></bio><bio xml:lang="ru"><p>603093 Нижний Новгород, ул. Деловая, 11/1</p></bio><xref ref-type="aff" rid="aff7"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">Медицинский радиологический научный центр им. А.Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">City Clinical Oncological Dispensary</institution></aff><aff><institution xml:lang="ru">СПб ГБУЗ «Городской клинический онкологический диспансер»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine</institution></aff><aff><institution xml:lang="ru">ГАУЗ «Челябинский областной клинический центр онкологии и ядерной медицины»</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">Sverdlovsk Regional Oncological Dispensary</institution></aff><aff><institution xml:lang="ru">ГАУЗ СО «Свердловский областной онкологический диспансер»</institution></aff></aff-alternatives><aff-alternatives id="aff6"><aff><institution xml:lang="en">Perm Regional Oncological Dispensary</institution></aff><aff><institution xml:lang="ru">ГБУЗ ПК «Пермский краевой онкологический диспансер»</institution></aff></aff-alternatives><aff-alternatives id="aff7"><aff><institution xml:lang="en">Research Institute of Clinical Oncology, Nizhny Novgorod Regional Clinical Oncological Dispensary</institution></aff><aff><institution xml:lang="ru">ГАУЗ НО «Научно-исследовательский институт клинической онкологии «Нижегородский областной клинический онкологический диспансер»</institution></aff></aff-alternatives><aff-alternatives id="aff8"><aff><institution xml:lang="en">Center of Outpatient Oncological Care, Moscow Multidisciplinary Clinical Center “Kommunarka”, Moscow Healthcare Department</institution></aff><aff><institution xml:lang="ru">Центр амбулаторной онкологической помощи ГБУЗ г. Москвы «Московский многопрофильный клинический центр «Коммунарка» Департамента здравоохранения г. Москвы»</institution></aff></aff-alternatives><aff-alternatives id="aff9"><aff><institution xml:lang="en">Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan named after prof. M.Z. Sigal</institution></aff><aff><institution xml:lang="ru">ГАУЗ «Республиканский клинический онкологический диспансер Минздрава Республики Татарстан им. проф. М.З. Сигала»</institution></aff></aff-alternatives><aff-alternatives id="aff10"><aff><institution xml:lang="en">Tambov Regional Oncological Clinical Dispensary</institution></aff><aff><institution xml:lang="ru">ГБУЗ «Тамбовский областной онкологический клинический диспансер</institution></aff></aff-alternatives><aff-alternatives id="aff11"><aff><institution xml:lang="en">Ivanovo Regional Oncological Dispensary</institution></aff><aff><institution xml:lang="ru">ОБУЗ «Ивановский областной онкологический диспансер»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-08-04" publication-format="electronic"><day>04</day><month>08</month><year>2024</year></pub-date><volume>14</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>98</fpage><lpage>107</lpage><history><date date-type="received" iso-8601-date="2024-08-04"><day>04</day><month>08</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-08-04"><day>04</day><month>08</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Borodavina E.V., Kutukova S.I., Shurinov A.Y., Vasil’eva E.B., Guz A.O., Grishkevich I.V., Karateeva S.D., Shakhmatova A.R., Slobodyanskiy R.S., Romanchuk O.V., Mukhitova M.R., Karpovich M.P., Dmitriev S.P., Saypeeva O.S., Tolpeykina K.A., Tolstov S.S., Makarova A.V., Tyugina Y.A., Ovchinnikova E.G.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Бородавина Е.В., Кутукова С.И., Шуринов А.Ю., Васильева Е.Б., Гузь А.О., Гришкевич И.В., Каратеева С.Д., Шахматова А.Р., Слободянский Р.С., Романчук О.В., Мухитова М.Р., Карпович М.П., Дмитриев С.П., Сайпеева О.С., Толпейкина К.А., Толстов С.С., Макарова А.В., Тюгина Я.А., Овчинникова Е.Г.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Borodavina E.V., Kutukova S.I., Shurinov A.Y., Vasil’eva E.B., Guz A.O., Grishkevich I.V., Karateeva S.D., Shakhmatova A.R., Slobodyanskiy R.S., Romanchuk O.V., Mukhitova M.R., Karpovich M.P., Dmitriev S.P., Saypeeva O.S., Tolpeykina K.A., Tolstov S.S., Makarova A.V., Tyugina Y.A., Ovchinnikova E.G.</copyright-holder><copyright-holder xml:lang="ru">Бородавина Е.В., Кутукова С.И., Шуринов А.Ю., Васильева Е.Б., Гузь А.О., Гришкевич И.В., Каратеева С.Д., Шахматова А.Р., Слободянский Р.С., Романчук О.В., Мухитова М.Р., Карпович М.П., Дмитриев С.П., Сайпеева О.С., Толпейкина К.А., Толстов С.С., Макарова А.В., Тюгина Я.А., Овчинникова Е.Г.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ogsh.abvpress.ru/jour/article/view/986">https://ogsh.abvpress.ru/jour/article/view/986</self-uri><abstract xml:lang="en"><p>Differentiated thyroid cancer is one of the most common malignant diseases of the endocrine system. Usually, it responds well to the standard treatment (surgery + radioiodine therapy), especially at early stages. During both treatment and dynamic observation, distant metastases are detected in 10–15 % of patients. In these cases, the patients continue treatment with radioactive iodine. If tumor cells have insufficient ability to capture and retain 131I or completely lose this ability, the effect of radioiodine therapy becomes limited and the disease progresses during therapy which leads to 5–10 % decrease in 10-year survival. The main problem in treatment of differentiated thyroid cancer is communication between radiologists in centers performing radioiodine therapy and clinical oncologists performing surgeries and observation at patient’s place of residence. For both specialists, the main goal is to identify clinical situations where early and effective treatment intervention can be beneficial without the risk of overdiagnosis and excessive treatment.</p><p>The article considers common questions arising during multidisciplinary interactions with radiologists of radioiodine centers and presents concise guidelines on the observation and treatment procedures for patients with differentiated thyroid cancer.</p></abstract><trans-abstract xml:lang="ru"><p>Дифференцированный рак щитовидной железы является одним из самых распространенных злокачественных заболеваний эндокринной системы. Чаще всего он хорошо поддается стандартному лечению (хирургия + радиойодтерапия), особенно на ранних стадиях. В процессе как лечения, так и динамического наблюдения у 10–15 % пациентов выявляется отдаленное метастазирование. В таких случаях больные продолжают лечение радиоактивным йодом. при недостаточно выраженной или постепенно утраченной способности опухолевых клеток захватывать и удерживать 131I эффект радиойодтерапии резко ограничивается либо заболевание прогрессирует на фоне проводимой терапии, что приводит к снижению показателей 10-летней выживаемости до 5–10 %. Основная проблема в процессе лечения дифференцированного рака щитовидной железы – сложность коммуникации между радиологами центров, где проводится радиойодтерапия, и клиническими онкологами, которые оперируют и затем наблюдают пациента по месту жительства. Для обоих специалистов главной задачей является определение тех клинических ситуаций, при которых есть польза от раннего и эффективного лечебного вмешательства, оптимизации терапии и при этом отсутствует риск гипердиагностики и избыточного лечения.</p><p>В статье рассмотрены вопросы, которые наиболее часто возникают в рамках мультидисциплинарных взаимодействий с радиологами радиойодцентров, а также даны ответы в наиболее сжатой форме по порядку наблюдения и лечения пациентов с дифференцированным раком щитовидной железы.</p></trans-abstract><kwd-group xml:lang="en"><kwd>differentiated thyroid cancer</kwd><kwd>radioiodine-refractory cancer</kwd><kwd>systemic therapy</kwd><kwd>lenvatinib</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>дифференцированный рак щитовидной железы</kwd><kwd>радиойодрефрактерный рак</kwd><kwd>системная терапия</kwd><kwd>ленватиниб</kwd></kwd-group><funding-group><funding-statement xml:lang="en">This publication has been prepared with the financial support of Eisai. The authors are solely responsible for the content of the publication and editorial decisions</funding-statement><funding-statement xml:lang="ru">Данная публикация подготовлена при финансовой поддержке компании «Эйсай». Авторы несут полную ответственность за содержание публикации и редакционные решения</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Rumyantsev P.O., Fomin D.K., Rumyantseva U.V. Criteria of well-differentiated thyroid carcinoma resistance to radioiodine therapy. Opukholi golovy i shei = Head and Neck Tumors 2014;(3):4–9. (In Russ.). DOI: 10.17650/2222-1468-2014-0-3-4-9</mixed-citation><mixed-citation xml:lang="ru">Румянцев П.О., Фомин Д.К., Румянцева У.В. Критерии радиойодрезистентности высокодифференцированного рака щитовидной железы к терапии радиоактивным йодом. Опухоли головы и шеи 2014;(3):4–9. DOI: 10.17650/2222-1468-2014-0-3-4-9</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><mixed-citation>Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary andfollicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892–9. DOI: 10.1210/jc.2005-2838</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Eustatia-Rutten C.F., Corssmit E.P., Biermasz N.R. et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91(1):313–9. DOI: 10.1210/jc.2005-1322</mixed-citation></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Shurinov A.Yu., Borodavina E.V., Krylov V.V. et al. Guidelines for radioiodine therapy in differentiated thyroid cancer and posttherapeutic follow-up. Opukholi golovy i shei = Head and Neck Tumors 2024;14(1):83–95. (In Russ.). DOI: 10.17650/2222-1468-2024-14-1-83-95</mixed-citation><mixed-citation xml:lang="ru">Шуринов А.Ю., Бородавина Е.В., Крылов В.В. и др. Методические рекомендации по проведению радиойодтерапии при дифференцированном раке щитовидной железы и посттерапевтическому контролю. Опухоли головы и шеи 2024;14(1): 83–95. DOI: 10.17650/2222-1468-2024-14-1-83-95</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Choinzonov E.L., Reshetov I.V., Ivanov S.A. et al. Draft of clinical guidelines for the diagnosis and treatment of differentiated thyroid cancer in adult patients. Endokrinnaya khirurgiya = Endocrine Surgery 2022;16(2):5–29. (In Russ.). DOI: 10.14341/serg12792</mixed-citation><mixed-citation xml:lang="ru">Чойнзонов Е.Л., Решетов И.В., Иванов С.А. и др. Проект клинических рекомендаций по диагностике и лечению дифференцированного рака щитовидной железы у взрослых пациентов. Эндокринная хирургия 2022;16(2):5–29. DOI: 10.14341/serg12792</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><mixed-citation>Haugen B., Alexander E., Bible Keith C. et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26(1):1–133. DOI: 10.1089/thy.2015.0020</mixed-citation></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Shurinov A.Yu., Borodavina E.V. Follow-up after radioiodine remnant ablation in differentiated thyroid cancer: the view of nuclear medicine physician. Opukholi golovy i shei = Head and Neck Tumors 2023;13(1):91–101. (In Russ.). DOI: 10.17650/2222-1468-2023-13-1-91-101</mixed-citation><mixed-citation xml:lang="ru">Шуринов А.Ю., Бородавина Е.В. Динамический контроль после радиойодабляции при дифференцированном раке щитовидной железы: взгляд радиолога. Опухоли головы и шеи 2023;13(1):91–101. DOI: 10.17650/2222-1468-2023-13-1-91-101</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><mixed-citation>Biondi B., Cooper D.S. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 2010;20(2):135–46. DOI: 10.1089/thy.2009.0311</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228–47. DOI: 10.1016/j.ejca.2008.10.026</mixed-citation></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Bolotina L.V., Vladimirova L.Yu., Dengina N.V. et al. Practical guidelines on drug treatment of head and neck tumors. RUSSCO practical guidelines, part 1. Zlokachestvennie opukholi = Malignant Tumors 2023;13:100–19. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Болотина Л.В., Владимирова Л.Ю., Деньгина Н.В. и др. Практические рекомендации по лекарственному лечению опухолей головы и шеи. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли 2023;13:100–19.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><mixed-citation>Schlumberger M., Brose M., Elisei R. et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 2014;2(5):356–8. DOI: 10.1016/S2213-8587(13)70215-8</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Berdelou A., Lamartina L., Klain M. et al. Treatment of refractory thyroid cancer. Endocr Relat Cancer 2018;25(4):R209–23. DOI: 10.1530/ERC-17-0542</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Tuttle R.M., Brose M.S., Grande E. et al. Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab 2017;31(3):295–305.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Castagna M.G., Maino F., Cipri C. et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 2011;165(3):441–6. DOI: 10.1530/EJE-11-0466</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Gruber J.J., Colevas A.D. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. Oncologist 2015;20(2):113–26. DOI: 10.1634/theoncologist.2014-0313</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Durante C., Attard M., Torlontano M. et al. Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas. J Clin Endocrinol Metab 2010;95(11):4882–8. DOI: 10.1210/jc.2010-0762</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Grani G., Lamartina L., Cantisani V. et al. Interobserver agreement of various thyroid imaging reporting and data systems. Endocr Connect 2018;7(1):1–7. DOI: 10.1530/EC-17-0336</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Lamartina L., Grani G., Biffoni M. et al. Risk stratification of neck lesions detected sonographically during the follow-up of differentiated thyroid cancer. J Clin Endocrinol Metab 2016;101(8):3036–44. DOI: 10.1210/jc.2016-1440</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Leenhardt L., Erdogan M.F., Hegedus L. et al. 2013 European Thyroid Association Guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J 2013;2(3):147–59. DOI: 10.1159/000354537</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Sgouros G., Kolbert K.S., Sheikh A. et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-Dimensional-Internal Dosimetry (3D-ID) software. J Nucl Med 2004;45(8):1366–72.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Robbins R.J., Wan Q., Grewal R.K. et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxyD-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006. DOI: 10.1210/jc.2005-1534</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Leboulleux S., El Bez I., Borget I. et al. Post-radioiodine treatment whole body scan in the era of fluorodesoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels. Thyroid 2012. DOI: 10.1089/thy.2012-0081</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>NCCN Clinical Practice Guidelines in Oncology Thyroid Carcinoma. Version 4.2023. August 16, 2023. NCCN. Published online 2023. DOI: 10.1001/jamaoncol.2018.2706</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Taylor M.H., Takahashi S., Capdevila J. et al. Correlation of performance status and neutrophil-lymphocyte ratio with efficacy in radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. Thyroid 2021;31(8):1226–34. DOI: 10.1089/thy.2020.0779</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Tahara M., Kiyota N., Hoff A.O. et al. Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer 2021;147:51–7. DOI: 10.1016/j.ejca.2020.12.032</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Brose M.S., Panaseykin Y., Konda B. et al. A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. J Clin Endocrinol Metab 2022;107(3):776–87. DOI: 10.1210/clinem/dgab731</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Tahara M., Brose M.S., Wirth L.J. et al. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer 2019;106:61–8. DOI: 10.1016/j.ejca.2018.10.002</mixed-citation></ref></ref-list></back></article>
